Publication Details

Category Text Publication
Reference Category Journals
DOI 10.1200/jco.2004.22.90140.9654
Title (Primary) Protein profiling utilizing SELDI technology may detect ductal carcinoma in situ (DCIS) with high reliability in patient's serum
Author Meinhold-Heerlein, I.; Mundhenke, C.; Rosel, F.; Jonat, W.; Nagasaki, K.; von Bergen, M.; Maass, N.
Source Titel Journal of Clinical Oncology
Year 2004
Department PROTEOM
Volume 22
Issue 14S
Page From 9654
Language englisch
Abstract Background: Several methods are suited to classify different cancer types by testing RNA or protein expression. There is no method available to screen for DCIS. This study was performed to differentiate normal, premalignant, and malignant cases by protein profiling of human serum samples. In addition, the diagnostic value of SELDI-MS (surface-enhanced laser desorption ionisation -mass spectroscopy) for early diagnosis of DCIS was investigated. Methods: SELDI-MS potentiates quantitative measurement of complex protein mixtures such as blood serum. According to their isoelectric point, proteins of 5 to 200 kDa were separated on a mass spectroscopy sample carrier, and then analysed. Based on the obtained protein profiles, algorithms to predict the sample type were developed. Blood samples from about thirty women were analysed including cases without any breast-related lesion, with lesions of premalignant, and malignant phenotype, respectively. Results: SELDI analysis revealed a good differentiation between premalignant lesions and normal controls. For DCIS, the prediction strength was more than 80%; 12 different proteins were differentially expressed, four of them were used for the set-up of a decision tree. In contrast, due to their heterogeneity the protein expression spectra of patients with invasive breast cancer did not reach a significant prediction strength. Conclusion: Utilizing SELDI technique, the identification of differentially expressed proteins in serum samples -related to women with tumors of different malignant progression -turned out to be possible. In addition, the method may become available to predict the existence of DCIS, or to detect other pre-invasive lesions.
Persistent UFZ Identifier
Meinhold-Heerlein, I., Mundhenke, C., Rosel, F., Jonat, W., Nagasaki, K., von Bergen, M., Maass, N. (2004):
Protein profiling utilizing SELDI technology may detect ductal carcinoma in situ (DCIS) with high reliability in patient's serum
J. Clin. Oncol. 22 (14S), 9654 10.1200/jco.2004.22.90140.9654